HepQuant Lab Meets COLA – CLIA Quality Standards
DENVER (Aug. 24, 2022) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that the HepQuant laboratory has achieved COLA accreditation for laboratory quality assurance. COLA is a third-party accreditation organization that ensures labs comply with federal…
Preliminary data from the HepQuant SHUNT-V Pivotal study presented at DDW® 2022
SAN DIEGO (May 24, 2022) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced preliminary data from the SHUNT-V Pivotal study in oral and poster presentations at Digestive Disease Week® (DDW) 2022 in San Diego….
Chris Jensen Joins Business Advisory Board
Former J.P. Morgan Investment Banker Brings Mid-Market Capital-Raising Experience to Board DENVER (May 10, 2022) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that former J.P. Morgan Investment Banker Chris Jensen has…
Bobbi Coffin Named to Business Advisory Board
Biodesix Exec and Former Exact Sciences Commercial Leader Adds Marketing Depth to Board Denver, CO – May 5, 2022 – HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that Bobbi Coffin, has joined the company’s…
Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial
Pharma and Medical Device Veteran Ally Xu Named Director of Regulatory and Quality Affairs
HepQuant Names Pharma and Medical Device Veteran Ally Xu Director of Regulatory and Quality Affairs DENVER (Feb. 1, 2022) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that pharmaceutical and medical device industry veteran…
Preliminary data from the HepQuant SHUNT-V Pivotal study released during the 72nd AASLD Annual Meeting
HepQuant Results Presented while Attending the 72nd AASLD Annual Meeting and AHA 2021 Annual Meeting DENVER (November 16th, 2021) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that preliminary data from the SHUNT-V Pivotal study…
Perspectum and HepQuant Announce Partnership to Bring a More Complete Picture of Liver Health
Perspectum and HepQuant Announce Partnership to Bring a More Complete Picture of Liver Health Partnership Combines Imaging and Functional Assessment for Clinical Research San Francisco, CA and Denver, CO – Nov. 1, 2021. Perspectum and HepQuant are proud to announce a strategic business partnership to provide seamless delivery of HepQuant’s…
HepQuant’s Greg Everson, MD, to Speak at AASLD/FDA Conference on Drug-Induced Liver Injury (DILI)
HepQuant’s Greg Everson, MD, to Speak at AASLD/FDA Conference on Drug-Induced Liver Injury (DILI) DENVER (April 14th, 2021) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that it will present at the 2021 AASLD/FDA Conference…
HepQuant Promotes Sean Bundy to Chief Operating Officer
HepQuant Promotes Sean Bundy, RAC, to Chief Operating Officer Denver, CO – June 10, 2020 – HepQuant, LLC, a Greenwood Village, Colo.-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced the promotion of Sean Bundy, RAC, to the…